treatment

Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive…

Infection rates were consistently lower in adults with neuromyelitis optica spectrum disorder (NMSOD) treated with Enspryng (satralizumab-mwge) over other immunosuppressive therapies, according to long-term data from clinical trials and real-world settings. “This analysis provides reassurance that the [Enspryng] safety profile observed in patients with NMOSD in a clinical…

Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses after six months, with many reducing their use of corticosteroids and other immunosuppressants. Nearly one-third of patients were able to stop corticosteroids, which can cause serious side effects when used…

Note: This column describes the author’s own experiences with various medication side effects. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Living with neuromyelitis optica spectrum disorder (NMOSD) feels like navigating a series of trade-offs. One of the most…

Starting off-label treatment with tocilizumab after the first disease attack in neuromyelitis optica spectrum disorder (NMOSD) is more effective at reducing disability than switching to tocilizumab after other therapies fail to control the disease, a study shows. Still, the risk of relapse over three years remained the same regardless…

Regular maintenance treatment with low-dose rituximab is associated with less disability and fewer relapses among people with neuromyelitis optica spectrum disorder (NMOSD) compared with receiving irregular doses of the preventive therapy, according to a two-year real-world study in China. “Regular [rituximab] treatment can significantly reduce the annual relapse rate, incidence…

Switching from Soliris (eculizumab) to Enspryng (satralizumab) is a safe and effective approach for neuromyelitis optica spectrum disorder (NMOSD) patients testing positive for antibodies against the AQP4 protein. That’s according to data from five patients in the U.S. who switched treatments due to either preference for route…

Neuromyelitis optica spectrum disorder (NMOSD) is largely known for its effect on the central nervous system, but the associated skin issues are often overlooked. For those of us living with NMOSD, the skin can become a silent messenger, reflecting the internal battle happening within our body. From goose…

Note: This column describes the author’s early experiences with Ultomiris (ravulizumab-cwvz) and refers to past therapies she’s tried. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I find myself whispering silent prayers throughout the day, pleading for my neuromyelitis…

Selecting healthcare practitioners is a daunting task, especially when you’re diagnosed with a rare disease like neuromyelitis optica spectrum disorder (NMOSD). I visited several physiotherapists, massage therapists, and dietitians before settling on my current team. Through my experiences, I’ve discovered the key questions to ask up front to determine…